Hoseinzadeh Saghar, Atashi Amir, Soleimani Masoud, Alizadeh Effat, Zarghami Nosratollah
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
In Vitro Cell Dev Biol Anim. 2016 Apr;52(4):479-87. doi: 10.1007/s11626-015-9992-x. Epub 2016 Jan 28.
The repair of skeletal defects is the main goal of bone tissue engineering. Recent literature highlighted various regulatory roles of microRNAs in stem cell fate determination. In addition, the role of porous hydroxyapatite/polycaprolacton (nHA/PCL) as a bioactive scaffold which enhances adipose tissue-derived mesenchymal stem cells (AT-MSCs) growth and osteogenic differentiation has been proved. The aim of the present study was to investigate the synergistic potential of both down-regulating miR-221 and nHA/PCL scaffold seeding in osteogenic potential of AT-MSCs. After isolation and characterization of AT-MSCs, the transfection of anti-miR-221 was performed into the cells using lipofectamine 2000 and the transfected cells were seeded into a synthesized nHA/PCL scaffold. The DAPI staining confirmed the presence of AT-MSCs on nHA/PCL scaffold. Quantitative expression of osteoblast marker genes, Runx2, and osteocalcin of the transfected cells in the scaffold were evaluated. Interestingly, significant upregulation of transcribed Runx2 and osteocalcin genes (P < 0.01) were observed in miR-221-inhibited nHA/PCL seeded cells. Also, alkaline phosphatase activity (ALP) was significantly higher (P < 0.01) in miR-221-inhibited AT-MSCs seeded on nHA/PCL than those seeded on nHA/PCL or transfected with anti-miR-221, individually. The results of this combination suggest a valuable method for enhancing osteogenesis in AT-MSCs. This method could be applicable for gene-cell therapy of bone defects.
骨骼缺损的修复是骨组织工程的主要目标。最近的文献强调了微小RNA在干细胞命运决定中的各种调节作用。此外,多孔羟基磷灰石/聚己内酯(nHA/PCL)作为一种生物活性支架,可促进脂肪组织来源的间充质干细胞(AT-MSCs)生长和成骨分化,其作用已得到证实。本研究的目的是探讨下调miR-221和接种nHA/PCL支架两者协同作用对AT-MSCs成骨潜能的影响。在分离和鉴定AT-MSCs后,使用脂质体2000将抗miR-221转染到细胞中,并将转染后的细胞接种到合成的nHA/PCL支架上。DAPI染色证实了nHA/PCL支架上存在AT-MSCs。评估了支架中转染细胞中成骨细胞标记基因Runx2和骨钙素的定量表达。有趣的是,在接种了miR-221抑制的nHA/PCL的细胞中,观察到转录的Runx2和骨钙素基因显著上调(P < 0.01)。此外,接种在nHA/PCL上的miR-221抑制的AT-MSCs中的碱性磷酸酶活性(ALP)显著高于单独接种在nHA/PCL上或用抗miR-221转染的细胞(P < 0.01)。这种联合作用的结果提示了一种增强AT-MSCs成骨作用的有价值方法。该方法可应用于骨缺损的基因细胞治疗。